Cipla
NSI:CIPLA · INE059A01026
PharmaceuticalsX-Large
360
53
Value42
Quality44
Growth42
Safety67
Sentiment58
Value Creation13/20creating some value
- Creates more value than its capital costs
- Owner earnings growing
- Owner earnings per share growing
- Reinvests at strong returns
- Solid earnings base
What this means
Cipla clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.
Based on 3/5 components.
Profile
CountryIndia
IndustryPharmaceuticals
SizeX-Large
TypePublic Company
ExchangeNSEI
Founded1935
Employees18,278
Websitecipla.com
ISININE059A01026
Last UpdateApr 2, 2026
Indices
Themes
CardiovascularDiabetesCentral Nervous SystemRespiratoryUrologyInfectious DiseasesOncologyVaccinesNeurologyHealth CareMedicalPharmaceutical
Description
Analysis
Middle-of-the-road
Cipla Limited sits in the middle of our grid: average quality, average price, no obvious signal in either direction.
360° rank · history
1007550250
94
2023202420252026
All-time high
96
Oct 2025
All-time low
41
Mar 2026
Average rank
77
across all years
Detailed & Historical Ranks
Deep dive into 15 detailed ranks and 3 years of history.
Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.
Similar Stocks
The companies this stock is ranked against.
Sun Pharmaceuticals
NSI:SUNPHARMA
55
CountryIndia
IndustryPharmaceuticals
SizeX-Large
Full Stock Analysis →
Alembic Pharmaceuticals
NSI:APLLTD
51
CountryIndia
IndustryPharmaceuticals
SizeLarge
Full Stock Analysis →
Make Sense of the Ranks
Every rank runs 1–100 against true peers. Higher is always better.
360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100